Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-03-08 @ 3:37 PM
Study NCT ID:
NCT00478634
Status:
COMPLETED
Last Update Posted:
2012-11-02
First Post:
2007-05-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions: